What PD-1 Receptor Does Pembrolizumab Bind To?
Pembrolizumab (Keytruda) is a monoclonal antibody that specifically binds to the programmed cell death protein 1 (PD-1) receptor on T-cells. This binding blocks PD-1's interaction with its ligands, PD-L1 (CD274) and PD-L2 (PDCD1LG2), preventing immune suppression and enabling T-cell activation against tumors [1].
How Does Pembrolizumab's Binding Mechanism Work?
Pembrolizumab binds to the extracellular domain of human PD-1 with high affinity (Kd ≈ 2-28 nM, depending on assay). It sterically hinders PD-1 from docking with PD-L1/PD-L2, disrupting the inhibitory signal pathway. This restores T-cell proliferation and cytokine production, key to its antitumor effects in cancers like melanoma and non-small cell lung cancer [1][2].
Does It Bind Anything Else on PD-1 or Related Targets?
Pembrolizumab is highly specific to PD-1 and does not bind PD-L1 directly (unlike drugs like atezolizumab). No significant off-target binding to other checkpoints like CTLA-4 has been reported in clinical data [2].
How Does This Compare to Other PD-1 Inhibitors Like Nivolumab?
| Drug | Manufacturer | PD-1 Binding Affinity (Kd) | Key Difference |
|------|--------------|----------------------------|---------------|
| Pembrolizumab | Merck | 2-28 nM | IgG4 isotype; half-life ~23 days |
| Nivolumab (Opdivo) | Bristol Myers Squibb | 2.8 nM | IgG4 with S228P mutation for reduced ADCC; half-life ~25 days [2][3] |
Both block PD-1/PD-L1 interaction similarly, but pembrolizumab shows slightly variable affinity across studies.
Clinical Implications of PD-1 Binding Specificity
This binding drives responses in PD-L1-high tumors, with FDA approvals tied to expression levels (e.g., TPS ≥1% for NSCLC). Resistance can arise from PD-L1 mutations or alternative pathways like LAG-3 [2].
[1]: FDA Label for Keytruda
[2]: DrugPatentWatch.com - Pembrolizumab Patents
[3]: NEJM - Pembrolizumab vs Nivolumab Review